AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37782540 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigability features
Number of subjects: 67
Study 37782758 — intervention group
Group type: EXPERIMENTAL
Intervention: Luspatercept
Number of subjects: 336
Study 37782888 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral LSAM-PTX (15 mg/mL)
Number of subjects: 32
Study 37782904 — intervention group
Group type: EXPERIMENTAL
Intervention: Control-IQ technology
Number of subjects: 0
Study 37782930 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient new-onset AF during hospitalization
Number of subjects: 139
Study 37782930 — intervention group
Group type: COMPARATOR
Intervention: Matched control participants without AF
Number of subjects: 139
Study 37783219 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable cabotegravir
Number of subjects: 570
Study 37783219 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate plus emtricitabine
Number of subjects: 570
Study 37783219 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 570
Study 37783221 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1222
Number of subjects: 1394
Study 37783221 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD2816
Number of subjects: 1394
Study 37783378 — intervention group
Group type: EXPERIMENTAL
Intervention: Simnotrelvir alone
Number of subjects: 88
Study 37783378 — intervention group
Group type: EXPERIMENTAL
Intervention: Simnotrelvir/ritonavir
Number of subjects: 88
Study 37783378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 37783453 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholera conjugate vaccine (CCV) OSP:rTTHc
Number of subjects: 0
Study 37783456 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 148
Study 37783456 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood sampling
Number of subjects: 148
Study 37783459 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined homestead food production and food hygiene intervention
Number of subjects: 574
Study 37783459 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 574
Study 37783480 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37783805 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex vivo drug response profiling
Number of subjects: 80
Study 37783805 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex vivo resistance to chemotherapeutic drugs
Number of subjects: 80
Study 37783805 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex vivo response to chemotherapy
Number of subjects: 80
Study 37783805 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex vivo drug response profiles
Number of subjects: 80
Study 37783947 — intervention group
Group type: EXPERIMENTAL
Intervention: MSC therapy
Number of subjects: 0
Study 37783947 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 37783966 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine, cisplatin, plus nivolumab
Number of subjects: 76
Study 37783969 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloxacillin plus fosfomycin
Number of subjects: 215
Study 37783969 — intervention group
Group type: COMPARATOR
Intervention: Cloxacillin alone
Number of subjects: 215
Study 37783970 — intervention group
Group type: EXPERIMENTAL
Intervention: Elranatamab monotherapy
Number of subjects: 88
Study 37784006 — intervention group
Group type: EXPERIMENTAL
Intervention: lacosamide
Number of subjects: 138
Study 37784006 — intervention group
Group type: EXPERIMENTAL
Intervention: eslicarbazepine
Number of subjects: 138
Study 37784006 — intervention group
Group type: EXPERIMENTAL
Intervention: perampanel
Number of subjects: 138
Study 37784006 — intervention group
Group type: EXPERIMENTAL
Intervention: brivaracetam
Number of subjects: 138
Study 37784006 — intervention group
Group type: EXPERIMENTAL
Intervention: topiramate
Number of subjects: 138
Study 37784006 — intervention group
Group type: EXPERIMENTAL
Intervention: zonisamide
Number of subjects: 138
Study 37784053 — intervention group
Group type: EXPERIMENTAL
Intervention: EGYFIL™ topical lotion
Number of subjects: 26
Study 37784086 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based walking program (standard approach)
Number of subjects: 400
Study 37784086 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based walking plus civic engagement program (combined approach)
Number of subjects: 400
Study 37784098 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed antibiotic prescription (DAP)
Number of subjects: 39
Study 37784098 — intervention group
Group type: COMPARATOR
Intervention: Immediate antibiotic prescription (IAP)
Number of subjects: 39
Study 37784098 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic prescription (NAP)
Number of subjects: 39
Study 37784109 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening frequency (once vs. at least twice daily)
Number of subjects: 760
Study 37784109 — intervention group
Group type: EXPERIMENTAL
Intervention: SBT technique (pressure support + positive end-expiratory pressure)
Number of subjects: 760
Study 37784109 — intervention group
Group type: COMPARATOR
Intervention: T-piece (as a comparison to pressure support + positive end-expiratory pressure)
Number of subjects: 760
Study 37784110 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral L-citrulline (5 g every 12 hours for 5 days)
Number of subjects: 120
Study 37784110 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isonitrogenous, isocaloric)
Number of subjects: 120
Study 37784131 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak anti-Factor Xa values
Number of subjects: 408
Study 37784131 — intervention group
Group type: EXPERIMENTAL
Intervention: Trough anti-Factor Xa values
Number of subjects: 408
Study 37784193 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Eating Index (HEI) score and physical activity
Number of subjects: 68
Study 37784193 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 68
Study 37784193 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Eating Index (HEI) score
Number of subjects: 68
Study 37784197 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise therapy program
Number of subjects: 0
Study 37784197 — intervention group
Group type: COMPARATOR
Intervention: Training program with range of motion exercises
Number of subjects: 0
Study 37784200 — intervention group
Group type: EXPERIMENTAL
Intervention: Walk-up no-cost testing
Number of subjects: 7500
Study 37784200 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker (promotores)-facilitated testing and preventive care counseling
Number of subjects: 7500
Study 37784200 — intervention group
Group type: EXPERIMENTAL
Intervention: Vending machines dispensing no-cost, self-testing kits
Number of subjects: 7500
Study 37784200 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategy bundle
Number of subjects: 7500
Study 37784200 — intervention group
Group type: EXPERIMENTAL
Intervention: Community and Scientific Advisory Board (CSAB) engagement
Number of subjects: 7500
Study 37784199 — intervention group
Group type: EXPERIMENTAL
Intervention: Active iTBS (intermittent theta burst stimulation) applied over the left dorsolateral prefrontal cortex (DLPFC) for ten sessions, once a day.
Number of subjects: 96
Study 37784199 — intervention group
Group type: COMPARATOR
Intervention: Sham iTBS applied over the left dorsolateral prefrontal cortex (DLPFC) for ten sessions, once a day.
Number of subjects: 96
Study 37784232 — intervention group
Group type: EXPERIMENTAL
Intervention: Core stabilization training for 8 weeks, 5 days/week
Number of subjects: 30
Study 37784232 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 30
Study 37786277 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg resmetirom
Number of subjects: 2000
Study 37786277 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg resmetirom
Number of subjects: 2000
Study 37786277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2000
Study 37786277 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment in MAESTRO-NAFLD-OLE
Number of subjects: 2000
Study 37786277 — intervention group
Group type: EXPERIMENTAL
Intervention: Resmetirom
Number of subjects: 2000
Study 37786336 — intervention group
Group type: EXPERIMENTAL
Intervention: Resectoscope sheath size (specific size not mentioned)
Number of subjects: 0
Study 37786336 — intervention group
Group type: COMPARATOR
Intervention: Control group (specific details not mentioned)
Number of subjects: 0
Study 37786390 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (maximum dose, 2500 mg)
Number of subjects: 510
Study 37786390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 510
Study 37786390 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 510
Study 37786396 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide (5 mg, 10 mg, 15 mg)
Number of subjects: 1428
Study 37786396 — intervention group
Group type: COMPARATOR
Intervention: Insulin Lispro
Number of subjects: 1428
Study 37786396 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide (pooled)
Number of subjects: 1428
Study 37786396 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Number of subjects: 1428
Study 37786451 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 4 mg/kg
Number of subjects: 12
Study 37786451 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 6 mg/kg
Number of subjects: 12
Study 37786451 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg/kg
Number of subjects: 12
Study 37786451 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (all doses)
Number of subjects: 12
Study 37786680 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotiraciclib (ZTR), a CDK9 inhibitor
Number of subjects: 0
Study 37786777 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent theta-burst stimulation (iTBS) for varying lengths (1 to 4 weeks)
Number of subjects: 0
Study 37786777 — intervention group
Group type: COMPARATOR
Intervention: Sham-control group
Number of subjects: 0
Study 37786824 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program
Number of subjects: 218
Study 37787009 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-IFNa + TDF (180 μg PEG-IFNa weekly plus 300 mg TDF once daily)
Number of subjects: 120
Study 37787009 — intervention group
Group type: COMPARATOR
Intervention: PEG-IFNa + placebo (180 μg PEG-IFNa weekly plus placebo)
Number of subjects: 120
Study 37787009 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-IFNa + TDF
Number of subjects: 120
Study 37787009 — intervention group
Group type: COMPARATOR
Intervention: PEG-IFNa + placebo
Number of subjects: 120
Study 37787025 — intervention group
Group type: EXPERIMENTAL
Intervention: MAG-EPA (3.75 g daily)
Number of subjects: 130
Study 37787025 — intervention group
Group type: COMPARATOR
Intervention: HOSO (3.75 g daily)
Number of subjects: 130
Study 37787428 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous sacral nerve stimulation (tSNS) with pelvic floor exercises (PFEs)
Number of subjects: 92
Study 37787432 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-Hz taVNS
Number of subjects: 300
Study 37787432 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-Hz taVNS
Number of subjects: 300
Study 37787432 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 300
Study 37787643 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual magnetic resonance with cholangiopancreatography or endoscopic ultrasound
Number of subjects: 156
Study 37787644 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital application tool for computing guideline-recommended follow-up intervals
Number of subjects: 29
Study 37787644 — intervention group
Group type: COMPARATOR
Intervention: No access to the digital application (control group)
Number of subjects: 29
Study 37787675 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT) plus best medical management
Number of subjects: 0
Study 37787675 — intervention group
Group type: COMPARATOR
Intervention: Best medical management alone
Number of subjects: 0
Study 37787793 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment (mean adherence 3.1 hours per day)
Number of subjects: 4186
Study 37787793 — intervention group
Group type: EXPERIMENTAL
Intervention: Good adherence to CPAP (≥4 hours per day)
Number of subjects: 4186
Study 37787793 — intervention group
Group type: COMPARATOR
Intervention: No CPAP (usual care)
Number of subjects: 4186
Study 37787790 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1 blockade plus lenvatinib
Number of subjects: 103
Study 37787796 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC) with cuff pressure ≤200 mm Hg (n=749)
Number of subjects: 1500
Study 37787796 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment with cuff pressure 20 mm Hg (n=751)
Number of subjects: 1500
Study 37787815 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative oncology (IO) treatment program
Number of subjects: 597
Study 37787815 — intervention group
Group type: EXPERIMENTAL
Intervention: PCP narratives
Number of subjects: 597
Study 37787888 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-ratio combination (basal insulin + GLP-1RA)
Number of subjects: 305
Study 37787888 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of basal insulin plus an SGLT-2 inhibitor (gliflo-combo)
Number of subjects: 305
Study 37787888 — intervention group
Group type: COMPARATOR
Intervention: Basal-bolus insulin regimen
Number of subjects: 305
Study 37787906 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 123
Study 37787941 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-alpha-reductase inhibitors (5-ARIs)
Number of subjects: 7618
Study 37787941 — intervention group
Group type: COMPARATOR
Intervention: No treatment (5-ARIs naïve)
Number of subjects: 7618
Study 37788048 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Determination Theory (SDT)-driven intervention delivered via email, coupled with a wearable activity monitor and PA recommendations
Number of subjects: 47
Study 37788048 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 47
Study 37788049 — intervention group
Group type: EXPERIMENTAL
Intervention: PEER intervention (8-week Physio-Feedback Exercise Program)
Number of subjects: 340
Study 37788060 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile mindfulness training with neurofeedback assistance
Number of subjects: 92
Study 37788060 — intervention group
Group type: COMPARATOR
Intervention: Mobile mindfulness training without neurofeedback
Number of subjects: 92
Study 37788060 — intervention group
Group type: COMPARATOR
Intervention: Self-learning paper materials on stress management
Number of subjects: 92
Study 37788078 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed mobile and web-based intervention (Mission Reconnect) for veterans with chronic pain and PTSD
Number of subjects: 364
Study 37788078 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed mobile and web-based intervention (Mission Reconnect)
Number of subjects: 364
Study 37788078 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 364
Study 37788108 — intervention group
Group type: EXPERIMENTAL
Intervention: Agricultural livelihood intervention (water pump, seeds, agricultural and financial training)
Number of subjects: 720
Study 37788108 — intervention group
Group type: COMPARATOR
Intervention: Standard of HIV care (control)
Number of subjects: 720
Study 37788412 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg canakinumab once every 3 weeks for 18 cycles
Number of subjects: 1382
Study 37788412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1382
Study 37788412 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg canakinumab
Number of subjects: 1382
Study 37788414 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-based PP-CSF standing order entry (SOE)
Number of subjects: 32
Study 37788414 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 32
Study 37788414 — intervention group
Group type: COMPARATOR
Intervention: Alert to not prescribe PP-CSF
Number of subjects: 32
Study 37788676 — intervention group
Group type: EXPERIMENTAL
Intervention: risankizumab 600 mg
Number of subjects: 198
Study 37788676 — intervention group
Group type: EXPERIMENTAL
Intervention: risankizumab 1200 mg
Number of subjects: 198
Study 37788676 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 198
Study 37788676 — intervention group
Group type: EXPERIMENTAL
Intervention: risankizumab 180 mg
Number of subjects: 198
Study 37788676 — intervention group
Group type: EXPERIMENTAL
Intervention: risankizumab 360 mg
Number of subjects: 198
Study 37788676 — intervention group
Group type: COMPARATOR
Intervention: placebo (withdrawal)
Number of subjects: 198
Study 37788676 — intervention group
Group type: EXPERIMENTAL
Intervention: risankizumab (induction)
Number of subjects: 198
Study 37788676 — intervention group
Group type: EXPERIMENTAL
Intervention: risankizumab (maintenance)
Number of subjects: 198
Study 37788924 — intervention group
Group type: EXPERIMENTAL
Intervention: MAC treatment with macrolides, rifamycin, ethambutol, amikacin and/or fluoroquinolones
Number of subjects: 100
Study 37788924 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug exposure
Number of subjects: 100
Study 37788924 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum inhibitory concentration (MIC) determination
Number of subjects: 100
Study 37788927 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified health education ('I')
Number of subjects: 2230
Study 37788927 — intervention group
Group type: EXPERIMENTAL
Intervention: RITe (transport reimbursement, intensified health education, and telephonic tracing)
Number of subjects: 2230
Study 37788927 — intervention group
Group type: EXPERIMENTAL
Intervention: Full intervention (RITe)
Number of subjects: 2230
Study 37788927 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 2230
Study 37788927 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with genital warts
Number of subjects: 2230
Study 37788928 — intervention group
Group type: EXPERIMENTAL
Intervention: self-guided internet-delivered intervention
Number of subjects: 50
Study 37789121 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 150
Study 37789228 — intervention group
Group type: EXPERIMENTAL
Intervention: XJ-procedure group
Number of subjects: 183
Study 37789228 — intervention group
Group type: COMPARATOR
Intervention: CARS group
Number of subjects: 183
Study 37789266 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-ICU patients (Bern cohort)
Number of subjects: 192
Study 37789266 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-ICU patients (Lausanne cohort)
Number of subjects: 192
Study 37789266 — intervention group
Group type: COMPARATOR
Intervention: Non-ICU patients
Number of subjects: 192
Study 37789266 — intervention group
Group type: EXPERIMENTAL
Intervention: Calprotectin levels
Number of subjects: 192
Study 37789286 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Circle Deprescribing Module (QC-DeMo) intervention
Number of subjects: 26
Study 37789300 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% Silver Diamine Fluoride (SDF) solution
Number of subjects: 165
Study 37789300 — intervention group
Group type: COMPARATOR
Intervention: 5% Sodium Fluoride (NaF) varnish combined with Motivational Interviewing (MI)
Number of subjects: 165
Study 37789329 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketofol 1:1 ratio
Number of subjects: 74
Study 37789329 — intervention group
Group type: COMPARATOR
Intervention: Ketofol 1:3 ratio
Number of subjects: 74
Study 37789340 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharyngeal electrical stimulation
Number of subjects: 0
Study 37789340 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37789376 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led deprescribing intervention using the MALPIP screening tool
Number of subjects: 14
Study 37789376 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 14
Study 37789376 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led deprescribing intervention
Number of subjects: 14
Study 37789389 — intervention group
Group type: EXPERIMENTAL
Intervention: PBO-Pyrethroid LLIN
Number of subjects: 7471
Study 37789389 — intervention group
Group type: COMPARATOR
Intervention: std-LLIN
Number of subjects: 7471
Study 37789461 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care model
Number of subjects: 528
Study 37789461 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 528
Study 37790170 — intervention group
Group type: EXPERIMENTAL
Intervention: NIATx implementation strategies
Number of subjects: 53
Study 37790171 — intervention group
Group type: EXPERIMENTAL
Intervention: TF-IDF method
Number of subjects: 113
Study 37790171 — intervention group
Group type: EXPERIMENTAL
Intervention: BERT method
Number of subjects: 113
Study 37790186 — intervention group
Group type: EXPERIMENTAL
Intervention: Train-the-trainer (TT) implementation support
Number of subjects: 61
Study 37790186 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced train-the-trainer (TT+) implementation support
Number of subjects: 61
Study 37790218 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention training technique (ATT) delivered in groups
Number of subjects: 0
Study 37790218 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control (WL)
Number of subjects: 0
Study 37790298 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromodulation (4 hours twice daily)
Number of subjects: 19
Study 37790298 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 19
Study 37790304 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter nadir-to-regain (2-4 days)
Number of subjects: 654
Study 37790304 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter nadir-to-regain (≤1 day)
Number of subjects: 654
Study 37790304 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative weight loss (-50 to <-23 percent-days)
Number of subjects: 654
Study 37790304 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative weight loss (≤-50 percent-days)
Number of subjects: 654